PDCD1 and neoplasm: Elevated serum concentrations of soluble LAG3 are seen in non-responders to anti-PD1 therapy and increased tumor infiltration with T cells positive for LAG3 and TIM3 was also correlated with shorter progression-free survival in patients receiving anti-PD1 immunotherapy (52, 90).